

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Jenscare Scientific Co., Ltd.**  
**寧波健世科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 9877)**

**VOLUNTARY ANNOUNCEMENT**  
**iJensRobo ROBOT-ASSISTED TTVR SYSTEM COMPLETES**  
**FIRST CLINICAL STUDY**

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business and product development of the Group.

The board (“**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that the Company’s iJensRobo robot-assisted transcatheter tricuspid valve replacement (TTVR) system has successfully completed its first clinical study.

Recently, the Company completed the first patient clinical study of iJensRobo robot-assisted TTVR system in Hong Kong. The operation employed the Company’s iJensRobo robot-assisted TTVR system to successfully implant a LuX-Valve Plus valve in a patient with severe tricuspid regurgitation. Post-operative echocardiography showed complete resolution of the patient’s tricuspid regurgitation, with no paravalvular leakage observed. The LuX-Valve Plus prosthetic valve was firmly anchored and demonstrated excellent stability.

This system is an innovative robot-assisted interventional therapy platform, designed to provide more precise, stable and controllable procedural support for TTVR procedures. Integrating high-precision motion control, active safety constraint mechanisms and intelligent navigation technologies, this system enables stable and delicate manipulation of devices, supporting the safety and reliability of key procedural steps.

Compared with conventional manual operation, iJensRobo robot-assisted TTVR system helps mitigate potential impacts arising from minor hand tremors, variations in operation range and spatial positioning deviations. By providing structured guidance for key procedural steps, it enhances procedural stability and consistency to a certain extent. Meanwhile, incorporating real-time control and safety restriction mechanisms, the system helps reduce risks associated with device displacement, erroneous manipulation and unstable operating paths during complex procedures, and lessens reliance on the individual experience of the operator to a certain degree.

In terms of system architecture, the platform adopts a master-slave control design, which reduces radiation exposure to the operator during interventional procedures and thereby improves occupational health risks. Furthermore, this system integrates remote operation functionality, with the potential to support cross-regional procedural collaboration and remote training.

**Cautionary Statement as required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** There is no assurance that the Company will ultimately market and/or commercialize robot-assisted transcatheter tricuspid valve replacement (TTVR) system successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board  
**Jenscare Scientific Co., Ltd.**  
**Mr. PAN Fei**

*Executive Director and Chief Executive Officer*

Hong Kong, 30 March 2026

*As at the date of this announcement, the executive Director is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.*